Rare Metabolic Bone Disease

  1.  Nirwan N, Jain S, Vohora D. Linagliptin-metformin combination: A novel approach to mitigate 4-vinyl cyclohexene di epoxide and dexamethasone-induced osteoporosis in mice. BONE 2025 Sep:198:117526. doi: 10.1016/j.bone.2025.117526. (Impact factor 3.5).
  2. Nirwan N, Anjaneyulu YP, Sultana Y, Vohora D. Development of linagliptin-loaded liposomes using aspartic acid conjugate for bone-targeted delivery to combat osteoporosis. J Drug Target. 2025 Jul; 33(6):1014-1025. doi: 10.1080/1061186X.2025.2467089 (Impact factor 4.3).
  3.  Jain S, Vohora D. Primary components of MCT ketogenic diet are detrimental to bone loss associated with accelerated aging and age-related neurotoxicity in mice. BONE 2025 Mar; 192:117383. doi: 10.1016/j.bone.2024.117383 (Impact factor 3.5).
  4. Gautam N, Sharma P, Chaudhary A, Sahu S, Vohora D, Mishra M, Dutta D, Singh M, Talegaonkar S. Investigating the osteogenic potential of bone-targeted daidzein-loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis: pharmacodynamic, biochemical, and genotoxicity evaluations. J Drug Targeting 2025 May 16: 1-16. doi: 10.1080/1061186X.2025.2503499 (Impact factor 4.3).
  5.  Shaik AR, Kohli S, Vohora D. Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2024 Jul; 213:111744. doi: 10.1016/j.diabres.2024.111744 (Impact factor 6.2).
  6.  Parveen B, Penumallu NR, Shaik AR, Parveen A, Parveen R, Vohora D. The impact of antiseizure medication on bone heath: A systematic review of animal studies. Epilepsy Research 2024 Feb; 200:107302. doi: 10.1016/j.eplepsyres.2024.107302 (IF 2.2).
  7.  Nirwan N, Vohora D. Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice. Frontiers in Endocrinology 2022 Jul 19;13:944323 (Impact factor 6.0).
  8.  Nirwan N, Nikita, Sultana Y, Vohora D. Liposomes as a multifaceted delivery system in the treatment of osteoporosis. Expert Opin Drug Deliv. 2021 Jun; 18(6):761-775. doi: 10.1080/17425247.2021.1867534 (Impact factor 6.64).
  9.  Jain S, Rai R, Singh D, Vohora D.Octanoic acid a major component of widely consumed medium-chain triglyceride ketogenic diet is detrimental to bone. Scientific Reports (Nature Publishing Group) 2021 Mar 26;11(1):7003. doi: 10.1038/s41598-021-86468-9.PMID: 33772066 (Impact factor 5.13).
  10.  Goel D, Vohora D. Liver X receptors and Skeleton: Current state-of-knowledge. BONE 2021 Mar 144:115807. (doi: 10.1016/j.bone.2020.115807) (Impact factor 4.5).
  11. Patra, S., Jena, S., Kedar, K., Pande, M., Katam, K. K., Prajapti, A., Kotecha, U., & Vyas, P. (2025). A novel SGMS2 mutation associated with high bone mass; description of an affected family with recurrent fragility fractures. Bone Reports, 24, 101833.
  12. Nagendra L, Agarwal K,Patra S, Bhattacharya S, Gupta L, Talwar N, et al. Optimizing Bone Health in Diabetes: Strategies for Fracture Risk Reduction in Public Healthcare. Curr Diab Rep [Internet] 2025 [cited 2025 Jul 24];25(1)
  13. Subbiah Sridhar, Muthu Aravind Kumar, Trapped cranial nerve and dense bones—sclerosteosis due to LRP4 mutation, QJM: An International Journal of Medicine, 2025;, hcaf190
  14. Calcium repletion to rats with calcipenic rickets fails to recover bone quality
  15. Kumar M, Jiloha RC, Kataria D, Prasad S, Vohora D. Effect of selective serotonin reuptake inhibitors on markers of bone loss.Psychiatry Research 2019 Jun;276:39-44.
  16. AmWadhwa R, Kumar M, Paudel YN, Iqbal R, Kothari P, Trivedi R, Vohora D. Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study.Journal of Bone Mineral Metabolism 2019 Jan;37(1):36-42
  17. Parveen B, Tiwari AK, Jain M, Pal S, Chattopadhyay N, Tripathi M, Vohora D. The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats. BONE 2018 Aug; 113: 57-67
  18. Kumar M, Wadhwa R, Kothari P, Trivedi R, Vohora D. Differential effects of serotonin reuptake inhibitors fluoxetine and escitalopram on bone markers and microarchitecture in Wistar rats.European Journal of Pharmacology 2018 Apr 15;825:57-62
  19. Vohora D, Parveen B. Tartarate resistant acid phosphatase as a biomarker of bone remodeling. In: Preedy VR (Ed) Biomarker in Bone Disease, Biomarkers in Disease: Methods, Discoveries and Applications, DOI 10.1007/978-94-007-7745-3_42-1, Springer Science+Business Media Dordrecht 2017.
  20. Kalam A, Talegaonkar S, Vohora D. Effects of raloxifene against letrozole-induced bone loss in chemically induced model of menopause in mice. Mol. Cell. Endocrinol. 2017; 440: 34-43
  21. Kalam A, Talegaonkar S, Vohora D. Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexenediepoxide treated ovotoxic female mice.FundamClinPharmacol. 2016; 30: 429-439
  22. Anwar MJ, Radhakrishna KV, Sharma A, Vohora D. Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice. European J Pharm Sci. 2014; 62: 219-226
  23. Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not levetiracetam induces bony alterations in female mice. Canadian J Physiol. Pharmacol. 2014; 92: 507-511
  24. Khanna S, Pillai KK, Vohora D. Bisphosphonates in phenytoin-induced bone disorder. BONE2011 (Mar); 48: 597-606
  25. Khanna S, Pillai KK, Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discovery Today 2009; 14: 428-434
  26. Clinical Focus Series: Bone and Mineral Disorders
  27. Pal R, Singla V, Bhadada SK. Osteogenesis imperfecta. QJM: An International Journal of Medicine. 2025 Apr 23:hcaf099
  28. Dhiman V, Aggarwal A, Raj NG, Dhaliwal R, Bhadada SK, Sachdeva N, Rao SD. Iatrogenic Osteoscierosis in Osteogenesis Imperfecta. InJOURNAL OF BONE AND MINERAL RESEARCH 2018 Nov 1 (Vol. 33, pp. 180-181). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
  29. Bhadada SK, Dhiman V, Dhaliwal R, Bhansali A, Van Hul W, Rao SD. Microarray Expression Profile Analysis and its Clinical Implication for the Treatment of Fibrogenesis Imperfecta Ossium. InJOURNAL OF BONE AND MINERAL RESEARCH 2018 Nov 1 (Vol. 33, pp. 183-183). 111 RIVER ST, HOBOKEN 07030- 5774, NJ USA: WILEY
  30. Pal R, Bhadada SK.Comment on “Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer”: Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget’s Disease of Bone.Osteoporos Int. 2022;33:2227-2228
  31. Pal R, Bhadada SK.Comment on “Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer”: Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget’s Disease of Bone. Osteoporos Int. 2022.
  32. Walia R, Dutta A, Gupta N, Bhansali A, Pivonello R, Ahuja CK, Dhandapani S, Dutta P, Bhadada SK, Simeoli C, Hajela A, Sachdeva N, Saikia UN.Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome.Endocr Pract. 2021;27:471-477.
  33. Dhiman V, Aggarwal A, Bhadada SK, Sachdeva N, Gopinathan NR and Dhawan DK. The Imapct of Bisphosphonates on the Osteoclast cells of osteogenesis imperfecta patients; Biomedical Pharmacology Journal, 2018;11: 645-651.
  34. Dutta A, Bhadada SK, Walia R.Anabolic Window-Like Phenomenon After Biochemical Remission in Cushing’s Syndrome: Does Surge in Bone Turnover Markers Correlate With Improved Bone Mineral Density? J Bone Miner Res. 2021.doi: 10.1002/jbmr.4337
  35. Dhiman V, Aggarwal A, Raj NG, Dhaliwal R, Bhadada SK, Sachdeva N, Rao SD. Iatrogenic Osteoscierosis in Osteogenesis Imperfecta. InJOURNAL OF BONE AND MINERAL RESEARCH 2018 Nov 1 (Vol. 33, pp. 180-181). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
  36. Dhiman V, Aggarwal A, Bhadada SK, Sachdeva N, Gopinathan NR and Dhawan DK. The Imapct of Bisphosphonates on the Osteoclast cells of osteogenesis imperfecta patients; Biomedical Pharmacology Journal, 2018;11: 645-651.